| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2075 | Fa-s2-ms4048 | Novel folate-caged pomalidomide-based anaplastic lymphoma kinase (ALK) PROTAC, effectively degrading ALK fusion proteins in cancer cells in a FOLR1-dependent manner |
|
| DCC2076 | Fasii-in-1 | Novel inhibitor of C. difficile's FASII pathway |
|
| DCC2077 | Fasn-in-41 | Novel potent and specific fatty acid synthase (FASN) inhibitor |
|
| DCC2078 | Fasn-in-56 | Novel fatty acid synthase (FASN) |
|
| DCC2079 | Fa-tlr7-54 | Novel folate-targeted TLR7 agonist, selectively accumulating in profibrotic macrophages and suppressing fibrosis-inducing cytokine production, reprograming M2-like fibrosis-inducing macrophages into fibrosis-suppressing macrophages, resulting in dramatic |
|
| DCC2080 | Fauc-113 | Dopamine D4 receptor antagonist |
|
| DCC2081 | Fauc150 | Novel irreversible dopamine D2 receptor ligand, covalently binding the L94C mutant of the dopamine D2 receptor |
|
| DCC2082 | Fauc-3019 | Dopamine D4 receptor antagonist |
|
| DCC2083 | Fauc-312 | Highly potent and selective dopamine D4 receptor agonist |
|
| DCC2084 | Fauc-346 | Potent and selective dopamine D3 receptor partial agonist |
|
| DCC2085 | Fba Inhibitor 2a11 | First-in-class covalent allosteric inhibitor of fructose-1,6-bisphosphate aldolase (FBA) from Candida albicans (CaFBA) |
|
| DCC2086 | Fb-pmt | Novel potent αvβ3 antagonist. reducing GBM tumor growth and viability by up to 98% |
|
| DCC2087 | Fc11409b | Novel CAIX inhibitor, inhibiting breast cancer invasion and metastasis |
|
| DCC2088 | Fc11a-2 | Specific inhibitor of inflammasome assembly, targeting the NLRP3 inflammasome by interfering with the proximity-induced autocleavage of procaspase-1 |
|
| DCC2089 | Fcpr16 | Novel phosphodiesterase 4 (PDE4) inhibitor with little emetic potential, blocking MPP+ induced oxidative damage in SH-SY5Y cells and neurons via AMPK-dependent autophagy |
|
| DCC2090 | Fc-rapa | Novel rapamycin derivative, targeting polycystic kidneys due to the high expression of the folate receptor (FRα), lacking the extra-renal effects of unconjugated rapamycin, in particular immunosuppressive effects |
|
| DCC2091 | Feiii-ppix Ligand-18 | Novel potent antimalarial agent, binding to ferriprotoporphyrin-IX (FeIII-PPIX) (Kd = 33 nM) against chloroquine-resistant and sensitive strains of Plasmodium falciparum |
|
| DCC2092 | Fenobam | Potent, selective, noncompetitive glutamate mGluR5 receptor antagonist |
|
| DCC2093 | Fenoprofen Calcium Dihydrate | Non-steroidal anti-inflammatory drug, being used for symptomatic relief for rheumatoid arthritis, osteoarthritis, and mild to moderate pain |
|
| DCC2094 | Fenspiride Hydrochloride | Non-steroidal antiinflammatory agent |
|
| DCC2095 | Ferric Maltol | Novel oral iron therapy agent, being effective in correcting iron deficiency anemia in patients with inflammatory bowel disease |
|
| DCC2096 | Ferroptosis Inducer | Novel ferroptosis inducer, killing selected cancer cell lines by harnessing reactive oxygen species (ROS) |
|
| DCC2097 | Ferroxamine B | Iron chelator, mediating iron transport in Streptomyces pilosus |
|
| DCC2098 | Ferulin C | Natural potent colchicine site binding microtubule-destabilizing agent with anti-proliferation and anti-metastasis activity via PAK1 and p21-mediated signaling in breast cancer cells |
|
| DCC2099 | Ffa2-agonist-1 | Selective orthosteric agonist of human FFA2 |
|
| DCC2100 | Ffa3-agonist-1 | Selective and moderately potent positive allosteric modular (PAM)-agonist of the FFA3 receptor |
|
| DCC2101 | Ffa3-antagonist-6 | Novel PAM-antagonist of the function of C3 at FFA3 |
|
| DCC2102 | ffn206 | Novel fluorescent probe as an excellent VMAT2 substrate capable of detecting VMAT2 activity in intact cells using fluorescence microscopy |
|
| DCC2103 | Fgf/pdgf/vegf Rtk Inhibitor | Potent, reversible, ATP-competitive inhibitor against PDGFRβ, FGFR-1, and VEGFR-2 (IC50 = 20, 90, and 240 nM, respectively) and effectively suppresses VEGF-stimulated proliferation of HMVECs (EC50 = 420 nM). |
|
| DCC2104 | Fgfr4 Inhibitor 1 | Novel, covalent, highly potent, and exquisitely specific FGFR4 inhibitor |
|
